Muhammet Özbilen: The Hidden Burden of BDUC
Muhammet Özbilen, Associate Professor Doctor at Ordu University, shared a post on LinkedIn:
“Iron Deficiency Update – Issue N5 is out
‘No diagnosis, but very real patients: Bleeding Disorder of Unknown Cause’
A patient bruises easily, bleeds after surgery, struggles with heavy periods and iron deficiency — yet every lab test is normal.
This isn’t the exception; it’s the rule. In up to two-thirds of adults with a mild-to-moderate bleeding tendency, no specific hemostatic abnormality is found.
They’re diagnosed with a Bleeding Disorder of Unknown Cause (BDUC) — the focus of Mehic et al.’s review in the International Journal of Laboratory Hematology.
Why it matters: These patients face impaired quality of life, real bleeding risk (especially around surgery and childbirth), and frequent iron deficiency.
Notably, up to 80% are women – a reminder of how often heavy menstrual bleeding is overlooked.
BDUC is a diagnosis of exclusion.
CFD, von Willebrand disease (VWD), and platelet function disorders must all be ruled out first.
Critical thresholds:
- Hemophilia A/B (FVIII/FIX): ISTH cutoff less than 40%, though studies suggest 50% may be clinically more relevant.
- VWD:
- VWF less than 50 IU/dL with bleeding – diagnostic;
- less than 30 IU/dL – diagnostic regardless of symptoms.
- Type 2 VWD: VWF:Act/Ag ratio less than 0.7.
Blind spots:
- A normal aPTT doesn’t exclude mild FVIII, IX, or XI deficiency.
- Factor XIII deficiency affects neither PT nor aPTT — routine testing will never catch it.
- The PFA-100/-200 can’t reliably separate PFD from BDUC. LTA remains the gold standard.
One measurement can mislead. VWF levels fluctuate with estrogen, age, and inflammation.
In Vienna Biobank data, nearly a quarter of VWD diagnoses were only established at follow-up — so repeat testing is essential.
Despite no unifying diagnosis, these patients share a real phenotype and real risk.
Management must go beyond labeling – toward individualized care ahead of hemostatic challenges.
Sometimes bleeding has no name on a lab report. But the patient, and the risk, are very real.
What’s your biggest challenge with BDUC patients? ”

Stay updated with Hemostasis Today.
-
Sep 2, 2026, 07:02Christoph B. Olivier: Rapid Platelet Inhibition in Acute Coronary Syndromes
-
Sep 2, 2026, 06:38Gene Therapy for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Sep 2, 2026, 06:32Sanjay Batra: Exploring What Lies Beyond Platelet Counts
-
Sep 2, 2026, 06:22Wolfgang Miesbach: A New Guideline for Critical Bleeding in ITP
-
Sep 2, 2026, 06:03Clémentine Sarkozy: A New Chapter for Hematology at Institut Curie
-
Sep 1, 2026, 18:13Ramsha Batool: Chemotherapy-Induced Anemia Impacts Quality of Life in Breast Cancer
-
Sep 1, 2026, 18:09Natalya Shynhera: Using Anemia to Teach Medical English in Real Clinical Practice
-
Sep 1, 2026, 18:06Wei Du: New Therapeutic Potential for PARP Inhibitors in MLL-Rearranged Leukemia
-
Sep 1, 2026, 18:03Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound